AN2 Therapeutics (ANTX) News
NASDAQ: ANTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
5.08-0.14 (-2.68%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANTX news summary
We found 3 recent headlines mentioning AN2 Therapeutics (ANTX): 1 in the past week and 2 in the past 30 days, most often from Nasdaq, Business Wire, PR Newswire. For price context, ANTX is down 2.68% at $5.08. The most recent story, "Biotech Stocks On The Rise - AKAN +88%, CUE +49%, ADAG +24%, ANTX +23%, NRXP +10%", was published by Nasdaq on Nov 18, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest AN2 Therapeutics headlines
- Biotech Stocks On The Rise - AKAN +88%, CUE +49%, ADAG +24%, ANTX +23%, NRXP +10%(RTTNews) - Shares of several biotech and healthcare companies moved higher amid clinical updates, quarterly results and increased trading activity. Akanda and Adagene rallied without fresh…NasdaqADAG, AKAN, ANTX, CUE
- AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific HighlightsMENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics…Business Wire
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating AN2 Therapeutics, Inc. (NASDAQ: ANTX) on behalf of the company's shareholders. The investigation…PR Newswire